Innoviva, Inc. engages in the development and commercialization of bio-pharmaceuticals. Its portfolio of respiratory products include RELVAR/BREO ELLIPTA, (fluticasone furoate/ vilanterol, FF/VI); ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI); and TRELEGY ELLIPTA (the combination FF/UMEC/VI). It has Long-Acting Beta2 Agonist collaboration agreement with GSK to develop and commercialize once-daily LABA products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was founded in 1996 and is headquartered in Brisbane, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone650-238-9600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$217.22 million
Profitability
Miscellaneous
Employees12
OptionableOptionable
Innoviva (NASDAQ:INVA) Frequently Asked Questions
What is Innoviva's stock symbol?
Innoviva trades on the NASDAQ under the ticker symbol "INVA."
How were Innoviva's earnings last quarter?
Innoviva Inc (NASDAQ:INVA) posted its earnings results on Wednesday, October, 31st. The biotechnology company reported $0.43 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.49 by $0.06. The biotechnology company had revenue of $61.70 million for the quarter, compared to the consensus estimate of $64 million. Innoviva had a negative return on equity of 110.01% and a net margin of 75.67%. The company's revenue was up 27.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.21 earnings per share. View Innoviva's Earnings History.
When is Innoviva's next earnings date?
What price target have analysts set for INVA?
2 equities research analysts have issued 1-year price targets for Innoviva's stock. Their forecasts range from $16.00 to $16.00. On average, they expect Innoviva's share price to reach $16.00 in the next year. This suggests that the stock has a possible downside of 18.7%. View Analyst Price Targets for Innoviva.
What is the consensus analysts' recommendation for Innoviva?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innoviva.
Has Innoviva been receiving favorable news coverage?
Media stories about INVA stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Innoviva earned a media sentiment score of 0.9 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the company's share price in the near future.
Who are some of Innoviva's key competitors?
Some companies that are related to Innoviva include Nektar Therapeutics (NKTR), Jazz Pharmaceuticals (JAZZ), Loxo Oncology (LOXO), SAGE Therapeutics (SAGE), Dr.Reddy's Laboratories (RDY), Perrigo (PRGO), Amarin (AMRN), GALAPAGOS NV/S (GLPG), Alkermes (ALKS), Catalent (CTLT), United Therapeutics (UTHR), FibroGen (FGEN), TESARO (TSRO), GW Pharmaceuticals PLC- (GWPH) and Amneal Pharmaceuticals (AMRX).
Who are Innoviva's key executives?
Innoviva's management team includes the folowing people:
- Mr. Geoffrey Hulme, Interim Principal Exec. Officer
- Ms. Marianne Zhen, Chief Accounting Officer (Age 50)
- Mr. Jeffrey A. Hagenah Ph.D., Chief Patent Counsel and VP
- Dr. Kevin Kwok, Head of Talent Acquisition & Strategy
- Dr. Edmund J. Moran Ph.D., VP and R&D Program Leader (Age 58)
Who are Innoviva's major shareholders?
Innoviva's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include TrimTabs Asset Management LLC (0.06%), Alpha Windward LLC (0.03%), Diligent Investors LLC (0.03%), Louisiana State Employees Retirement System (0.03%) and Bowling Portfolio Management LLC (0.01%). Company insiders that own Innoviva stock include Eric Desparbes, George B Abercrombie, Michael W Aguiar and Theodore J Jr Witek. View Institutional Ownership Trends for Innoviva.
Which major investors are selling Innoviva stock?
INVA stock was sold by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System and Diligent Investors LLC. Company insiders that have sold Innoviva company stock in the last year include Eric Desparbes, George B Abercrombie and Theodore J Jr Witek. View Insider Buying and Selling for Innoviva.
Which major investors are buying Innoviva stock?
INVA stock was acquired by a variety of institutional investors in the last quarter, including TrimTabs Asset Management LLC, Alpha Windward LLC and Bowling Portfolio Management LLC. View Insider Buying and Selling for Innoviva.
How do I buy shares of Innoviva?
Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Innoviva's stock price today?
One share of INVA stock can currently be purchased for approximately $19.67.
How big of a company is Innoviva?
Innoviva has a market capitalization of $1.97 billion and generates $217.22 million in revenue each year. The biotechnology company earns $134.14 million in net income (profit) each year or $1.17 on an earnings per share basis. Innoviva employs 12 workers across the globe.
What is Innoviva's official website?
How can I contact Innoviva?
Innoviva's mailing address is 2000 SIERRA POINT PARKWAY SUITE 500, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected]
MarketBeat Community Rating for Innoviva (NASDAQ INVA)
MarketBeat's community ratings are surveys of what our community members think about Innoviva and other stocks. Vote "Outperform" if you believe INVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
